ADC Therapeutics reported Q ended Dec 31, 2025 net loss of $6.4M ($0.04/share) versus a net loss of $30.7M ($0.29/share) a year earlier, a reduction of about $24.3M (~79%). Adjusted net loss was $13.5M. The sharp narrowing of the loss is a modestly positive operational development, though the company remains unprofitable.
ADC Therapeutics reported Q ended Dec 31, 2025 net loss of $6.4M ($0.04/share) versus a net loss of $30.7M ($0.29/share) a year earlier, a reduction of about $24.3M (~79%). Adjusted net loss was $13.5M. The sharp narrowing of the loss is a modestly positive operational development, though the company remains unprofitable.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
